NEWS

新闻资讯

公司新闻

查看全部

尧唐生物完成超亿元人民币A+轮融资,加速体内基因编辑药物开发

近日,全球体内基因编辑和碱基编辑技术开拓者尧唐生物宣布完成超亿元人民币A+轮融资,由德诚资本领投,广州产投和华方资本跟投。浩悦资本担任本轮独家财务顾问。自去年8月公司完成由远翼投资领投,险峰旗云、楹联健康基金和九合创投跟投的超亿元人民币A轮融资后,公司再次斩获超亿元融资。至此,尧唐生物A轮系列融资近3亿元。

论文刊物

查看全部

Fu, B., Liao, J., Chen, S., Li, W., Wang, Q., Hu, J., Yang, F., Hsiao, S., Jiang, Y., Wang, L., Chen, F., Zhang, Y., Wang, X., Li, D., Liu, M., &Wu, Y.2022. CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric beta(0)/beta(0) transfusion-dependent beta-thalassemia.Nat Med, 28: 1573–1580.


Demirci, S., Zeng, J.,Wu, Y., Uchida, N., Shen, A. H., Pellin, D., Gamer, J., Yapundich, M., Drysdale, C., Bonanno, J., Bonifacino, A. C., Krouse, A. E., Linde, N. S., Engels, T., Donahue, R. E., Haro-Mora, J. J., Leonard, A., Nassehi, T., Luk, K., Porter, S. N., Lazzarotto, C. R., Tsai, S. Q., Weiss, M. J., Pruett-Miller, S. M., Wolfe, S. A., Bauer, D. E., & Tisdale, J. F. 2020. BCL11A enhancer-edited hematopoietic stem cells persist in rhesus monkeys without toxicity.J Clin Invest, 130(12): 6677-6687.


Zeng, J.,Wu, Y., Ren, C., Bonanno, J., Shen, A. H., Shea, D., Gehrke, J. M., Clement, K., Luk, K., Yao, Q., Kim, R., Wolfe, S. A., Manis, J. P., Pinello, L., Joung, J. K., & Bauer, D. E. 2020. Therapeutic base editing of human hematopoietic stem cells.Nat Med, 26(4): 535-541.


Zhang, X., Chen, L., Zhu, B., Wang, L., Chen, C., Hong, M., Huang, Y., Li, H., Han, H., Cai, B., Yu, W., Yin, S., Yang, L., Yang, Z., Liu, M., Zhang, Y., Mao, Z.,Wu, Y., Liu, M., & Li, D. 2020a. Increasing the efficiency and targeting range of cytidine base editors through fusion of a single-stranded DNA-binding protein domain.Nat Cell Biol, 22(6): 740-750.

行业资讯

查看全部

Contact us

Tel :021-52260086 Email:info@yoltx.com

版权所有© 尧唐(上海)生物科技有限公司 沪公网安备31011202013743号

Powered By VTHINK

联系我们

info@yoltx.com

021-52260086